Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
about
Alemtuzumab for multiple sclerosisAlemtuzumab for multiple sclerosisMethotrexate for multiple sclerosisIntravenous immunoglobulins for multiple sclerosisSystematic imaging review: Multiple SclerosisOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionMultiple sclerosis-a quiet revolutionIssues and practices in multiple sclerosis.Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patientsThe diagnosis of multiple sclerosis and the clinical subtypes.Global N-acetylaspartate declines even in benign multiple sclerosisInterplay of hormones and p53 in modulating gender dimorphism of subventricular zone cell number.Cluster analysis of behavioural and event-related potentials during a contingent negative variation paradigm in remitting-relapsing and benign forms of multiple sclerosis.The patient's journey: multiple sclerosis.Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Overcoming the clinical-MR imaging paradox of multiple sclerosis: MR imaging data assessed with a random forest approach.Therapeutic developments in multiple sclerosis.Chemokine receptor antagonism as a new therapy for multiple sclerosis.Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosisSuppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.Sex differences in autoimmune diseases.Usability and potential of geostatistics for spatial discrimination of multiple sclerosis lesion patterns.Benign multiple sclerosis: does it exist?Adult gonadal hormones selectively regulate sexually dimorphic quantitative traits observed in experimental allergic encephalomyelitis.Age and disability accumulation in multiple sclerosis.Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)Interferon-beta1b for multiple sclerosis.Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.The impact of osteopontin gene variations on multiple sclerosis development and progression.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Female-specific issues in multiple sclerosis.Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders.Gender issues in multiple sclerosis: an update.Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis.Sex differences in the injured brain.Benign multiple sclerosis: aspects of cognition and neuroimaging.Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study.>CME/CNE ARTICLE: Severity Grading in Multiple Sclerosis: A Proposal.T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis.
P2860
Q24185899-23A68D28-D573-4AA1-B430-4FF14929C226Q24195076-D33F171D-65B8-42C8-BA94-85591CA50A8DQ24247245-AA8A4D5C-7107-4F6A-8DC7-AC27AF93237CQ24247968-E8A770FC-3D15-4EC1-B190-304DD9DBC14BQ26779905-C72D5A18-7D71-487C-99E6-8326EA5AA3C2Q26822611-F4F5EDAF-0FE9-4419-9B07-53B60C1348DCQ26826930-380A41FB-0217-4A81-B701-2D791DDF817DQ30751454-92D62499-2257-4745-92C5-2C11C3CDE5AFQ31141962-0F853C95-71E7-4B3B-9FC7-5601D426E57EQ33386254-334900EA-B52A-469F-A516-CC4836A1C7C7Q33670907-4F721136-E0B7-4E5B-B750-1F4CDB6847B5Q33725131-D706CBFC-C401-4DD7-895E-6E970A8F6757Q33827668-91843EF3-51DF-43E2-BB05-6D4B96BC3A17Q33920238-7EF899F4-2174-42CA-8B6C-CCACC0E11EA9Q33936390-2ECFF34F-EF5E-4C5A-B763-315CDF915798Q34045441-5B05C167-96F8-40F2-B843-6E6C53A1961CQ34073979-CBB6D150-8F9B-4D41-B734-D03C1565BA75Q34074776-0C397333-C2DD-4C96-A8D1-0886C6334BE3Q34074854-EF08D7FF-6DF9-4318-8713-25C1AF76000DQ34138065-16234A3A-A31F-4EF5-853A-1F3C49F81C6BQ34450447-119EF55E-09B5-41B8-83FE-35A3F6142795Q34498866-F914CCB2-1083-4E7C-8667-1861BFCDCAB7Q34577652-C2672158-AEE9-4F1C-978C-F9F5CBF6E8A4Q34640135-915886C5-1930-4EAD-A629-0D0794C4CFAEQ35083316-BD59BE93-BA8A-4DB0-84DA-72FEB0DE8899Q35230950-C1930F82-E1D5-4D8E-8BC4-147372BB22E2Q36077974-2A82B8D6-3383-4447-8A03-3916B4E29E55Q36106790-415641A3-0C9D-419C-B7D7-50BBF6D78256Q36190102-E2B48092-CE96-4FD2-AC77-637F8C0B5867Q36247916-42812790-9BCE-4B98-B6B6-C3E036E0A670Q36975701-5C3A220D-A6FF-491D-A73B-03A73833F510Q37174067-BE250ADB-84E4-4475-8AD2-AC65D255AFF6Q37795699-280B9B9F-5EF3-4181-B873-3610A1484385Q37813691-0F85BFA3-9B94-4E7D-8CB6-537B58304085Q38212036-1B9EEE9A-780A-4E31-AC55-F93A1FA96DBEQ38471576-9E9B2FB8-FD3F-497D-9C58-A76CC72A4DFDQ38704455-4218B7AD-CB38-4BCB-BC6D-79082B58A8B6Q39938023-B45709DC-482D-43B4-8EE6-5D5C13743D09Q41626910-E8D21957-6733-4C37-8D53-6D529D1BF01FQ42454590-8DB4823B-7796-462E-87D7-ADB37BC339DD
P2860
Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@ast
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@en
type
label
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@ast
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@en
prefLabel
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@ast
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@en
P2860
P356
P1476
Benign multiple sclerosis? Cli ...... essment of prognostic factors.
@en
P2093
Hawkins SA
McDonnell GV
P2860
P304
P356
10.1136/JNNP.67.2.148
P407
P577
1999-08-01T00:00:00Z